SM-030 for the Treatment of Melasma

We are pioneering a path to obtain FDA approval for targeting topical small molecule, SM-030, for the treatment of melasma.

Our capital efficient approach leveraged decades of combined team experience to run efficient clinical trials at a fraction of industry standard timelines and budgets.